Skip to Main Content

Paper Details

Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation.
J Immunother Cancer
9
2023
AT, CD47, CI-994, Grp3, MB, MYC, MYC amplified MB, MYC-driven MB, MYC-driven medulloblastoma, MYC-driven tumors, NF-B, NF-kB, SIRP, SIRPa, TGM2, Tacedinaline, anti-CD47 mAb, atypical, atypical teratoid/rhabdoid, atypical teratoid/rhabdoid tumor, calreticulin, cancer, children, class I HDACs, glioblastoma, histone, histone deacetylase, interferon, macrophage, medulloblastoma, mice, mouse, nuclear factor-kB, signal regulatory protein, transglutaminase 2, tumor, tumor inflammat
Author NameAffiliation
Viktoria MarquardtGerman Cancer Research Center (DKFZ)
Viktoria MarquardtInstitute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Dusseldorf
David PauckGerman Cancer Research Center (DKFZ)
David Pauckand Clinical Immunology, University Hospital Dusseldorf
Daniel PicardGerman Cancer Research Center (DKFZ)
Daniel Picardand Clinical Immunology, University Hospital Dusseldorf
Nan QinGerman Cancer Research Center (DKFZ)
Nan Qinand Clinical Immunology, University Hospital Dusseldorf
Lena Bl??melGerman Cancer Research Center (DKFZ)
Lena Bl??meland Clinical Immunology, University Hospital Dusseldorf
Jasmin BartlGerman Cancer Research Center (DKFZ)
Jasmin Bartland Clinical Immunology, University Hospital Dusseldorf
Frauke-Dorothee MeyerGerman Cancer Research Center (DKFZ)
Frauke-Dorothee MeyerInstitute of Neuropathology, Heinrich-Heine University Dusseldorf
Allison M ColeUniversity of Colorado Denver
Till MildeHopp Children's Cancer Center Heidelberg (KiTZ)
Till MildeHeidelberg University Hospital
Olaf WittHopp Children's Cancer Center Heidelberg (KiTZ)
Olaf WittClinical Cooperation Unit Pediatric Oncology, German Cancer Research Center (DKFZ) and German Consortium for Translational Cancer Research (DKTK)
Olaf WittHopp Children's Cancer Center Heidelberg (KiTZ)
Olaf WittClinical Cooperation Unit Pediatric Oncology, German Cancer Research Center (DKFZ) and German Consortium for Translational Cancer Research (DKTK)
Gabriel LeprivierInstitute of Neuropathology, Heinrich-Heine University Dusseldorf
Anja StefanskiBiomedical Research Centre (BMFZ), Heinrich-Heine University
Kai St??hlerBiomedical Research Centre (BMFZ), Heinrich-Heine University
Stephen T KeirDuke University
Stephen T KeirDuke University
Darell D BignerDuke University
Darell D BignerDuke University
Thomas BeezHeinrich-Heine University Dusseldorf
Ute Fischerand Clinical Immunology, University Hospital Dusseldorf
Rajeev VibhakarUniversity of Colorado Denver
Samuel H CheshierHuntsman Cancer Institute, University of Utah
Guido ReifenbergerGerman Cancer Research Center (DKFZ)
Guido ReifenbergerInstitute of Neuropathology, Heinrich-Heine University Dusseldorf
Arndt BorkhardtGerman Cancer Research Center (DKFZ)
Arndt BorkhardtHematology and Clinical Immunology, Heinrich-Heine-University
Arndt BorkhardtGerman Cancer Research Center (DKFZ)
Arndt BorkhardtHematology and Clinical Immunology, Heinrich-Heine-University
Marc RemkeGerman Cancer Research Center (DKFZ)
Marc Remkeand Clinical Immunology, University Hospital Dusseldorf
  • 1 - 40

Datasets

Release 1.2